Asset Details
Do you wish to reserve the book?
Biomarkers for predicting atrial fibrillation: An explorative sub-analysis of the randomised SCREEN-AF trial
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Biomarkers for predicting atrial fibrillation: An explorative sub-analysis of the randomised SCREEN-AF trial
Do you wish to request the book?
Biomarkers for predicting atrial fibrillation: An explorative sub-analysis of the randomised SCREEN-AF trial
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Biomarkers for predicting atrial fibrillation: An explorative sub-analysis of the randomised SCREEN-AF trial
2024
Overview
Atrial fibrillation (AF) is a common treatable risk factor for stroke. Screening for paroxysmal AF in general practice is difficult, but biomarkers might help improve screening strategies.
We investigated six blood biomarkers for predicting paroxysmal AF in general practice.
This was a pre-specified sub-study of the SCREEN-AF RCT done in Germany. Between 12/2017-03/2019, we enrolled ambulatory individuals aged 75 years or older with a history of hypertension but without known AF. Participants in the intervention group received active AF screening with a wearable patch, continuous ECG monitoring for 2x2 weeks and usual care in the control group. The primary endpoint was ECG-confirmed AF within six months after randomisation. High-sensitive Troponin I (hsTnI), brain natriuretic peptide (BNP), N-terminal pro-B-type natriuretic peptide (NT-pro BNP), N-terminal pro atrial natriuretic peptide (NT-ANP), mid-regional pro atrial natriuretic peptide (MR-pro ANP) and C-reactive protein (CRP) plasma levels were investigated at randomisation for predicting AF within six months after randomisation.
Blood samples were available for 291 of 301 (96.7%) participants, including 8 with AF (3%). Five biomarkers showed higher median results in AF-patients: BNP 78 vs. 41 ng/L (
= 0.012), NT-pro BNP 273 vs. 186 ng/L (
= 0.029), NT-proANP 4.4 vs. 3.5 nmol/L (
= 0.027), MR-pro ANP 164 vs. 125 pmol/L (
= 0.016) and hsTnI 7.4 vs. 3.9 ng/L (
= 0.012). CRP levels were not different between groups (2.8 vs 1.9 mg/L,
= 0.1706).
Natriuretic peptide levels and hsTnI are higher in patients with AF than without and may help select patients for AF screening, but larger trials are needed.
Publisher
Taylor & Francis Ltd,Taylor & Francis,Taylor & Francis Group
